Recursion(RXRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company achieved a 35% year-over-year reduction in pro forma operating expenses, coming in 10% below the guidance provided in May of the previous year [48][49] - The company ended the year with $754 million in cash and expects cash operating expenses for 2026 to be under $390 million, extending the cash runway to early 2028 [48][50] Business Line Data and Key Metrics Changes - The company reported significant progress in its clinical development, with a diversified portfolio and a positive proof of concept for FAP, which has the potential to be a first-in-class treatment [7][27] - The company synthesized 90% fewer compounds than the industry average, achieving 300 compounds synthesized compared to 2,500, and completed this process in an average of 17 months versus the industry standard of over 40 months [13][43] Market Data and Key Metrics Changes - The company has achieved over $500 million in total cash inflows from partnerships, including upfront payments and milestones, with each program having the potential for over $300 million in milestones and tiered royalties [34][35] Company Strategy and Development Direction - The company is focused on three strategic pillars: tangible proof points in clinical and partner programs, surgical investment in its platform, and disciplined execution to do more with less [10][11] - The company aims to leverage its integrated end-to-end operating system to improve decision-making across R&D, emphasizing the importance of high-quality data and innovative models [6][39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the broader momentum in the sector, highlighting the importance of translating insights into real applications and measurable impacts [2][3] - The company is on track for initial engagement with the FDA regarding REC-4881 and anticipates additional clinical data for various programs in the coming year [51][52] Other Important Information - The company has built over 50 petabytes of high-quality multimodal data, which is crucial for developing state-of-the-art foundation models in biology and chemistry [39][40] - The company continues to innovate in its clinical development AI platform, improving enrollment rates and operational efficiency [45][46] Q&A Session Summary Question: What is the potential registrational pathway for REC-4881? - The company is on track for initial engagement with the FDA in the first half of 2026 to discuss the registrational study design and patient population [54][55] Question: Are there any one-off cost-cutting measures that helped in Q4? - The focus has been on efficiency rather than one-off cost-cutting measures, with expectations to continue growing the pipeline while hitting cost targets [56][57] Question: What is the rationale behind the divestment from NVIDIA? - The divestment is part of NVIDIA's shift in investment strategy, while the technical collaboration with NVIDIA continues, focusing on leveraging automation and supercomputing capabilities [59][60]